Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)
Primary Purpose
Kidney Failure, Liver Failure, Chronic, Kidney-Pancreas Failure
Status
Recruiting
Phase
Phase 3
Locations
Austria
Study Type
Interventional
Intervention
Custodiol-N Solution
Custodiol HTK Solution
Sponsored by
About this trial
This is an interventional treatment trial for Kidney Failure
Eligibility Criteria
Inclusion Criteria:
- All organs (kidney, combined kidney - pancreas and liver) Donor criteria
- deceased adult (≥18 years) donors fulfilling the criteria for organ donation Patient (recipient) criteria
- recipients awaiting their transplant
- recipients ≥18 years
- recipients' signed informed consent before the transplantation Kidney / combined kidney - pancreas recipients
- n/a Liver recipient
- full organ transplantation
Exclusion Criteria:
- All organs (kidney, combined kidney - pancreas and liver) Donor criteria
- - donors whose organs are all allocated out of retrieving study center
- general refusal of organ donation
- donation after cardiac death (DCD) Patient (recipient) criteria
- pregnant or lactating patients
- recipients participating in any interventional study (e.g. another study involving compound/interventions aimed at the reduction of preservation and / or ischemia / reperfusion injury)
- all combined allocations other than pancreas and kidney
Kidney / combined kidney -pancreas recipient
- double kidney transplantation
- pancreas retransplantation
- machine perfusion According to the KDIGO-Guidelines (2009) all patients with PRA >0% are excluded
Liver recipient
- retransplantation
- machine perfusion
Sites / Locations
- Medical University GrazRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Active Comparator
Experimental
Active Comparator
Experimental
Active Comparator
Arm Label
Kidney Custodiol-N
Kidney Custodiol
Liver Custodiol-N
Liver Custodiol
Kidney/Pancreas Custodiol-N
Kidney/Pancreas Custodiol
Arm Description
Outcomes
Primary Outcome Measures
Kidney: - delayed graft function: Dialysis requirement during the first week af-ter transplantation
Liver: - area under the curve (AUC) GPT (ALT) after transplantation during 7 days (minimum 1 measurement per day)
Secondary Outcome Measures
Full Information
NCT ID
NCT03627013
First Posted
August 8, 2018
Last Updated
October 18, 2023
Sponsor
Dr. F. Köhler Chemie GmbH
1. Study Identification
Unique Protocol Identification Number
NCT03627013
Brief Title
Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)
Official Title
A Prospective, Randomized, Single Blind, Multicentre Phase III Study on Organ Preservation With Custodiol-N Solution Compared With Custodiol Solution in Or-gan Transplantation (Kidney, Liver and Pancreas)
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 23, 2019 (Actual)
Primary Completion Date
September 30, 2025 (Anticipated)
Study Completion Date
September 30, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. F. Köhler Chemie GmbH
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Synopsis Title of Study A prospective, randomized, single blind multicentre phase III study on organ preservation with Custodiol-N compared with Custodiol solution in organ transplantation (kidney, liver and pancreas)
Protocol number: CL-N-KLP-TX-III/07-AT/17
Trial design The study design is a prospective, randomized, single blind, multicentre, phase III comparison study of organ perfusion intended to demonstrate non-inferiority of Custodiol-N against Custodiol in organ transplantation of kidney, combined kidney-pancreas and liver.
Intended duration of study The overall duration for the trial is expected to be approximately 30 months. The du-ration of the trial for each subject is expected to be 3 months (transplantation and a follow-up period of 90 days).
Purpose of the study
The objective of this investigation is to demonstrate non-inferiority of graft preservation with Custodiol-N compared to Custodiol with respect to both graft function and injury after transplantation of kidney, liver or combined kidney-pancreas.
Patient selection The study population will be selected from patients who will undergo kidney, liver or combined kidney-pancreas transplantation. Patients of each gender will be included in the study.
Planned number of patients (recipients)
In total N=614 including:
Kidney 412 (including approx. 30 combined kidney-pancreas)
Liver 202
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Failure, Liver Failure, Chronic, Kidney-Pancreas Failure
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
614 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Kidney Custodiol-N
Arm Type
Experimental
Arm Title
Kidney Custodiol
Arm Type
Active Comparator
Arm Title
Liver Custodiol-N
Arm Type
Experimental
Arm Title
Liver Custodiol
Arm Type
Active Comparator
Arm Title
Kidney/Pancreas Custodiol-N
Arm Type
Experimental
Arm Title
Kidney/Pancreas Custodiol
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Custodiol-N Solution
Intervention Description
Perfusion
Intervention Type
Drug
Intervention Name(s)
Custodiol HTK Solution
Intervention Description
Perfusion
Primary Outcome Measure Information:
Title
Kidney: - delayed graft function: Dialysis requirement during the first week af-ter transplantation
Time Frame
7 days
Title
Liver: - area under the curve (AUC) GPT (ALT) after transplantation during 7 days (minimum 1 measurement per day)
Time Frame
7 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All organs (kidney, combined kidney - pancreas and liver) Donor criteria
deceased adult (≥18 years) donors fulfilling the criteria for organ donation Patient (recipient) criteria
recipients awaiting their transplant
recipients ≥18 years
recipients' signed informed consent before the transplantation Kidney / combined kidney - pancreas recipients
n/a Liver recipient
full organ transplantation
Exclusion Criteria:
All organs (kidney, combined kidney - pancreas and liver) Donor criteria
- donors whose organs are all allocated out of retrieving study center
general refusal of organ donation
donation after cardiac death (DCD) Patient (recipient) criteria
pregnant or lactating patients
recipients participating in any interventional study (e.g. another study involving compound/interventions aimed at the reduction of preservation and / or ischemia / reperfusion injury)
all combined allocations other than pancreas and kidney
Kidney / combined kidney -pancreas recipient
double kidney transplantation
pancreas retransplantation
machine perfusion According to the KDIGO-Guidelines (2009) all patients with PRA >0% are excluded
Liver recipient
retransplantation
machine perfusion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Astrid Friedel
Phone
+4332638578017
Email
astrid.friedel@medunigraz.at
Facility Information:
Facility Name
Medical University Graz
City
Graz
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Schemmer
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)
We'll reach out to this number within 24 hrs